20S Proteasome Test Your Knowledge

Test Your Knowledge

Quiz: Is This Triplet Regimen Safe to Treat R/R MM?

02/03/2022

True or false: Ixazomib with pomalidomide plus dexamethasone cannot be combined safely.

True or false: Ixazomib with...

02/03/2022

Oncology

Test Your Knowledge

Quiz: What Type of Ixazomib Combo Shows Improved Responses for Patients With MM?

12/09/2021

True or false: Triplet combinations including ixazomib for patients with MM have shown more efficacious results than doublet regimens in the relapse setting.

True or false: Triplet...

12/09/2021

Oncology

Test Your Knowledge

Quiz: What is the Role of the Ubiquitin-Proteasome System in Protein Degradation?

11/16/2021

Which of the following does the ubiquitin-proteasome system regulate?

Which of the following does the...

11/16/2021

Oncology

Test Your Knowledge

Quiz: Which Bladder Cancer Type Shows Elevated Concentrations of 20S Proteasome?

10/28/2021

Which of the following types of bladder cancer shows significantly elevated concentrations of both the 20S proteasome and UCH-L1?

Which of the following types of...

10/28/2021

Oncology

Quiz

Quiz: What is the Role of 20S Proteasome Molecules in MM?

09/29/2021

True or false: 20S proteasome molecules exhibit activity in MM.

True or false: 20S proteasome...

09/29/2021

Oncology

Quiz

Quiz: The Effects of P53 Levels in 20S Proteasome Functionality

08/03/2021

True or false: When the 20S proteasome is not functioning correctly, there is a decrease in p53 levels, which can induce mutated forms of p53, and ultimately lead to a variety of cancers.

True or false: When the 20S...

08/03/2021

Oncology

Test Your Knowledge

Quiz: The 2 Most Common MM Treatment Regimens

11/17/2020

The 2 most common treatment regimens administered to patients with MM are an RvD-like regimen and the combination of daratumumab, lenalidomide, and __________.

The 2 most common treatment...

11/17/2020

Oncology

Test Your Knowledge

Quiz: What Was the Purpose of the KarMMa Clinical Trial?

11/11/2020

True or False: In the KarMMA clinical trial, investigators looked at the use of anti-BCMA CAR-T therapy for relapsed/refractory MM.

True or False: In the KarMMA...

11/11/2020

Oncology

Test Your Knowledge

Quiz: Which Adverse Event is Most Common With Combo CAR-T Therapy for R/R MM?

09/03/2020

In a study by Dr Yan et al, the most common AE observed with the infusion of humanized anti-CD19 and anti-BCMA CAR T-cells in patients with relapsed or refractory MM was which of the following?

In a study by Dr Yan et al, the...

09/03/2020

Oncology

Test Your Knowledge

Quiz: Possible Correlation Between Disparities in MM Prognosis and Sociodemographic Factors?

08/25/2020

True or False: Findings suggest that a correlation may exist between low education levels and poor survival in patients with multiple myeloma in China.

True or False: Findings suggest...

08/25/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology